Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S7W-01709 · Session 7

What plans it has make representations to Pfizer regarding submitting a UK licensing application for the ACT-O-VIAL hydrocortisone system.

Answered Asked by Andrew Baxter LD Lodged 15 Jul 2026

The question

To ask the Scottish Government what plans it has make representations to Pfizer regarding submitting a UK licensing application for the ACT-O-VIAL hydrocortisone system.

The answer

Answered by Maree Todd on 10 Aug 2026 · 26 days after it was lodged, on time

The regulation and licensing of medicines is reserved to the UK Government and is a matter for the Medicines and Healthcare products Regulatory Agency (MHRA).The decision to market a product in the UK rests with the pharmaceutical company. Neither the MHRA nor the UK or Scottish Governments can compel a pharmaceutical company to seek a marketing authorisation for, or supply, a product in the UK market.The Chief Pharmaceutical Officer (CPO) for Scotland has discussed the issue with Pfizer representatives who advised that the company is continuing to assess whether it will pursue a UK marketing authorisation for its Solu-Cortef Act-O-Vial® 100 mg/2 mL injection.

In the Official Report

No contribution in the Official Report cites S7W-01709 by reference.